TENAX THERAPEUTICS, INC. (TENX): Nasdaq/NYSE listing notice — Tenax Therapeutics receives Nasdaq delisting notice; appoints interim CFO Lawrence Hoffman

TENAX THERAPEUTICS, INC.

Nasdaq notified Tenax on Jan 11, 2024 that it fails minimum 500,000 publicly held shares after 1-for-80 reverse split.
Company has until Feb 26, 2024 to submit a compliance plan; no immediate effect on listing or trading.
Lawrence Hoffman appointed Interim CFO effective Jan 11, 2024, succeeding Eliot Lurier (deceased).
Hoffman will be paid $416/hour through Danforth Advisors consulting agreement.

item 3.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eliot M. Lurier

Chief Financial Officer

TENX · TENAX THERAPEUTICS, INC.

Successor: Lawrence R. Hoffman
Filed: January 12, 2024, 6:59 PM ET

Mr. Hoffman succeeds Eliot M. Lurier, who passed away in December 2023

Appointed (interim)

Lawrence R. Hoffman

Interim Chief Financial Officer

TENX · TENAX THERAPEUTICS, INC.

Effective: 2024-01-11
Filed: January 12, 2024, 6:59 PM ET

On January 9, 2024, the Company’s Board of Directors (the “Board”) appointed Lawrence R. Hoffman as Interim Chief Financial Officer of the Company effective January 11, 2024

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

TENAX THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5550(a)(4)

Exact text from the filing

January 11, 2024, Tenax Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) regarding compliance with Nasdaq Listing Rule 5550(a)(4) (the “Rule”) which requires the Company to have a minimum of 500,000 publicly held shares. The letter from Nasdaq indicated that according to its calculations, as of January 3, 2024, the day after the Company effected a 1-for-80 reverse split of its common stock, the Company no longer meets the requirements of the Rule. This notice of noncompliance has no immediate impact on the cont

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eliot M. Lurier departed as Chief Financial Officer at TENAX THERAPEUTICS, INC..

Action: passed away
Role: Chief Financial Officer

Exact text from the filing

Mr. Hoffman succeeds Eliot M. Lurier, who passed away in December 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lawrence R. Hoffman was appointed as Interim Chief Financial Officer at TENAX THERAPEUTICS, INC..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On January 9, 2024, the Company’s Board of Directors (the “Board”) appointed Lawrence R. Hoffman as Interim Chief Financial Officer of the Company effective January 11, 2024

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-24-000523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.